Opinion
Video
Author(s):
Panelists discuss the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC), exploring main therapeutic approaches, the role of androgen deprivation monotherapy, the timing for adding chemotherapy and ARPIs, and strategies for sequencing or combining these modalities in clinical practice.
Anito-Cel Yields 100% Response Rate in R/R Myeloma
Durcabtagene Autoleucel Yields High Response Rates in R/R Myeloma
Daratumumab Plus VRd Improves MRD Negativity in Newly Diagnosed, Transplant-Ineligible or -Deferred Myeloma
Daratumumab/Lenalidomide Improves MRD– Conversion Rates in Newly Diagnosed Myeloma After ASCT
2 Commerce Drive
Cranbury, NJ 08512